Literature DB >> 26299768

MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C.

Gang Deng1, Yinglu Teng1, Feizhou Huang1, Wanpin Nie1, Lei Zhu1, Wei Huang1, Hongbo Xu1.   

Abstract

MicroRNAs (miRs) have important roles in the pathogenesis of human malignancy. It has previously been suggested that deregulation of miR‑101 is associated with the progression of intrahepatic cholangiocarcinoma (ICC); however, the exact role of miR‑101 in the regulation of ICC metastasis remains largely unknown. The present study demonstrated that the expression levels of miR‑101 were significantly decreased in ICC tissue, as compared with matched adjacent normal tissue. Furthermore, miR‑101 was downregulated in the ICC‑9810 human ICC cell line, as compared with in the normal human intrahepatic biliary epithelial cell (HIBEC) line. Vascular endothelial growth factor (VEGF)‑C was identified as a target gene of miR‑101 in ICC‑9810 cells. The expression of VEGF‑C was negatively regulated by miR‑101 at the post‑transcriptional level in ICC‑9810 cells. Further investigation demonstrated that overexpression of miR‑101 markedly suppressed the migration and invasion of ICC‑9810 cells, and these effects were similar to those observed following VEGF‑C knockdown. Conversely, restoration of VEGF‑C reversed the inhibitory effects of miR‑101 overexpression on ICC‑9810 cell migration and invasion, thus suggesting that miR‑101 may suppress ICC‑9810 cell migration and invasion, at least partly via inhibition of VEGF‑C. It was also demonstrated that the mRNA and protein expression levels of VEGF‑C were frequently upregulated in ICC tissue and cells, and its expression level was inversely correlated with that of miR‑101 in ICC tissue. In conclusion, the present study identified important roles for miR‑101 and VEGF‑C in ICC, suggesting that miR‑101/VEGF‑C signaling may be a promising diagnostic and/or therapeutic target for ICC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26299768     DOI: 10.3892/mmr.2015.4239

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  12 in total

1.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

2.  Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression.

Authors:  Yuu Saitoh; Tomohiro Umezu; Satoshi Imanishi; Michiyo Asano; Seiichiro Yoshizawa; Seiichiro Katagiri; Tamiko Suguro; Hiroaki Fujimoto; Daigo Akahane; Chiaki Kobayashi-Kawana; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

3.  CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells.

Authors:  Li-Hong Wang; Chih-Yang Lin; Shih-Chia Liu; Guan-Ting Liu; Yen-Ling Chen; Jih-Jung Chen; Chia-Han Chan; Ting-Yi Lin; Chi-Kuan Chen; Guo-Hong Xu; Shiou-Sheng Chen; Chih-Hsin Tang; Shih-Wei Wang
Journal:  Oncotarget       Date:  2016-06-14

4.  1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p.

Authors:  Yingyu Ma; Wei Luo; Brittany L Bunch; Rachel N Pratt; Donald L Trump; Candace S Johnson
Journal:  Oncotarget       Date:  2017-07-27

5.  Identification of biomarkers of intrahepatic cholangiocarcinoma via integrated analysis of mRNA and miRNA microarray data.

Authors:  Yaqing Chen; Dan Liu; Pengfei Liu; Yajing Chen; Huiling Yu; Quan Zhang
Journal:  Mol Med Rep       Date:  2017-01-16       Impact factor: 2.952

6.  Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs.

Authors:  Srinivas V Koduru; Ashley N Leberfinger; Yuka I Kawasawa; Milind Mahajan; Niraj J Gusani; Arun J Sanyal; Dino J Ravnic
Journal:  Sci Rep       Date:  2018-05-22       Impact factor: 4.379

7.  Role of cantharidin in the activation of IKKα/IκBα/NF‑κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines.

Authors:  Huijiang Zhou; Jiangfeng Xu; Shuai Wang; Jinfeng Peng
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

8.  Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells.

Authors:  Wei-Hung Yang; An-Chen Chang; Shih-Wei Wang; Shoou-Jyi Wang; Yung-Sen Chang; Tzu-Ming Chang; Shao-Keh Hsu; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

Review 9.  Molecular therapies delaying cardiovascular aging: disease- or health-oriented approaches.

Authors:  Alessandra Magenta; Reggio Lorde; Sunayana Begum Syed; Maurizio C Capogrossi; Annibale Puca; Paolo Madeddu
Journal:  Vasc Biol       Date:  2020-01-16

10.  Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway.

Authors:  Anli Yang; Fu Peng; Lewei Zhu; Xing Li; Shunling Ou; Zhongying Huang; Song Wu; Cheng Peng; Peng Liu; Yanan Kong
Journal:  Cell Death Dis       Date:  2021-07-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.